Garel N
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC H3T 1J4, Canada.
ArticlePsilocybin
Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.
ArticlePsilocybin
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
ArticleKetamine
Cognitive effects of intravenous Ketamine in treatment-resistant depression: A systematic review.
ArticleKetamine
The Montreal model of ketamine-therapy for alcohol use disorder and comorbid treatment-resistant depression: protocol for a feasibility trial.
ArticlePsilocybin
Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report.
ArticleKetamine
The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.
ArticleKetamine
The ketamine chameleon: history, pharmacology, and the contested value of experience.
ArticlePsilocybin
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
ArticleMDMA
Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022.
ArticleKetamine
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression.
ArticleKetamine
Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings.
ArticlePsilocybin
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
ArticlePsilocybin